Response rate of patients with baseline brain metastases from recently diagnosed non ‐small cell lung cancer receiving radiotherapy according to EGFR, ALK and KRAS mutation status
ConclusionsRT response varies as per tumor molecular status. The presence ofEGFR mutations favors the organ ‐specific response to RT, and is associated with longer OS in patients with NSCLC and BM.Key points
This study addressed for the first time the difference in radiotherapy ‐related outcomes in patients with different genotypes of non‐small cell lung cancer (NSCLC) before they received systemic therapy.
Results show that response to radiotherapy varies as per tumor molecular status, particularlyEGFR‐mutated tumors, have a favorable response to radiotherapy, contrary toKRAS‐mutated tumors.
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Oscar Arrieta,
Laura ‐Alejandra Ramírez‐Tirado,
Enrique Caballé‐Perez,
Alberto Mejia‐Perez,
Zyanya Lucia Zatarain‐Barrón,
Andrés F. Cardona,
Francisco Lozano‐Ruíz,
Manuel Segura‐González,
Graciela Cruz‐Rico,
Federico Maldona Tags: ORIGINAL ARTICLE Source Type: research
More News: Brain | Brain Cancers | Cancer | Cancer & Oncology | Chemotherapy | Genetics | Lung Cancer | Neurology | Non-Small Cell Lung Cancer | Study